Pfizer Inc.
PFE
Below: live stock price for Pfizer Inc. (PFE), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Pfizer Inc. (PFE) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 75,000 people. Over the past year PFE traded between 23.62 and 30.67 USD. Trailing P/E sits near 40.16 on a market cap of about 173.95B USD. It currently yields 5.64% in dividends.
- Prev close
- $29.95
- Volume (24h)
- $1.13B
- Market cap
- $173.95B
- Currency
- USD
Score
42/ 100 · Weak
- Value26
- Quality54
- Momentum49
- Growth32
- Risk68
- Dividend35
- Liquidity27
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 30.7056 +0.61%
- +20 bars
- 30.9634 +1.45%
- +60 bars
- 31.0638 +1.78%
- +120 bars
- 31.0675 +1.79%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.25% per bar.
Interpretation
Composite signals look weak. Strength: risk profile with weakness: valuation. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value26/100
Value looks fragile — driven by P/E (40.16).
P/E:40.16P/B:2.04PEG:13.72 - Quality54/100
Quality looks mixed — driven by Gross margin (74.72%).
ROE:5.01%ROA:5.78%Profit margin:6.80%Gross margin:74.72% - Momentum49/100
Momentum looks mixed — driven by 52w change (23.76%).
52w change:23.76% - Growth32/100
Growth looks weak — driven by Revenue growth (2.60%).
Revenue growth:2.60% - Risk68/100
Risk looks solid — driven by Debt / equity (74.25).
Beta:0.28Debt / equity:74.25Short interest:2.42% - Dividend35/100
Dividend looks weak — driven by Payout ratio (226.32%).
Dividend yield:5.64%Payout ratio:226.32% - Liquidity27/100
Liquidity looks fragile — driven by Current ratio (1.27).
Current ratio:1.27Quick ratio:0.85
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 21.7%
- Max drawdown
- -17.1%
- Below period high
- -0.5%
- Best day
- +4.59%
- Worst day
- -3.41%
- Up days
- 52%
- Current streak
- 2 up
- Typical day swing
- 2.0%
- Volume vs average
- -25%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 30.67 high → 26.05 low · 60 bars
- ResistanceFib +161.8% extensionnot reached38.1452 USD+24.98% from current
- ResistanceFib +100% extensionnot reached35.29 USD+15.63% from current
- ResistanceFib +61.8% extensionnot reached33.5252 USD+9.85% from current
- ResistanceFib +27.2% extensionnot reached31.9266 USD+4.61% from current
- Current30.52 USD
- SupportFib 23.6% retracementNearesttested 5×29.5797 USD-3.08% from current
- SupportFib 38.2% retracementtested 5×28.9052 USD-5.29% from current
- SupportFib 50% midpointtested 11×28.36 USD-7.08% from current
- SupportFib 61.8% retracementtested 16×27.8148 USD-8.86% from current
- SupportFib 78.6% retracementtested 2×27.0387 USD-11.41% from current
- SupportFib −27.2% extensionnot reached24.7934 USD-18.76% from current
- SupportFib −61.8% extensionnot reached23.1948 USD-24.00% from current
- SupportFib −100% extensionnot reached21.43 USD-29.78% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $30.67
- 52w low
- $23.62
- 52w change
- 23.76%
- Day high
- $30.67
- Day low
- $30.14
- P/E (TTM)
- 40.16
- Forward P/E
- 10.58
- PEG
- 13.72
- Price / Book
- 2.04
- Beta (5Y)
- 0.28
- Enterprise value
- 226.03B
- EV / Revenue
- 3.55
- EV / EBITDA
- 8.91
- EPS (TTM)
- $0.76
- Forward EPS
- $2.88
- Dividend yield
- 5.64%
- Dividend rate
- $1.72
- Payout ratio
- 226.32%
- Revenue (TTM)
- 63.7B
- EBITDA
- 25.38B
- Free cash flow
- 12.49B
- Total cash
- 11.7B
- Total debt
- 63.48B
- Debt / Equity
- 74.25
- Current ratio
- 1.27
- Quick ratio
- 0.85
- Profit margin
- 6.80%
- Gross margin
- 74.72%
- Return on assets
- 5.78%
- Return on equity
- 5.01%
- Shares outstanding
- 5.7B
- Float
- 5.69B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.28
- very stable
- 52-week change
- 23.76%
- Short % of float
- 2.42%
- Short ratio (days)
- 4.2
- Debt / Equity
- 74.25
- very high leverage
- Current ratio
- 1.27
- Quick ratio
- 0.85
- ROE
- 5.01%
- ROA
- 5.78%
- PEG ratio
- 13.72
- EV / Revenue
- 3.55
- EV / EBITDA
- 8.91
- Revenue growth
- 2.60%
- EBITDA
- 25.38B
- Free cash flow
- 12.49B
- Total cash
- 11.7B
- Total debt
- 63.48B
- Insider holdings
- 0.10%
- Institutional
- 69.11%
Recent rating changes
- 2026-10-09JP MorganNeutral → Neutralmain
- 2026-10-08Cantor FitzgeraldNeutral → Neutralmain
- 2026-10-06ScotiabankSector Outperform → Sector Outperformmain
- 2026-09-10HSBCHold → Holdmain
- 2026-08-07GuggenheimBuy → Buymain
- 2026-07-13BMO CapitalOutperform → Outperformmain
- 2026-07-13GuggenheimBuy → Buymain
- 2026-07-10B of A SecuritiesNeutral → Neutralmain
Financial documents
- Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PXN-PX2026-08-31
- Corporate Changes & Voting Matters8-K2026-08-04
- Corporate Changes & Voting Matters8-K2026-06-18
- Annual report of employee stock purchase11-K2026-06-16
- Offering RegistrationsS-82026-05-05
- Corporate Changes & Voting Matters8-K2026-04-27
- Proxy StatementsDEFA14A2026-03-12
- Periodic Financial Reports10-K2026-02-26
- Corporate Changes & Voting Matters8-K2026-02-03
- Corporate Changes & Voting Matters8-K2025-12-16
- Corporate Changes & Voting Matters8-K2025-11-21
- Corporate Changes & Voting Matters8-K2025-11-13
Recent news
- Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?Motley Fool7 hr. ago
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysMT Newswiresyesterday
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends24/7 Wall St.yesterday
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered CapsidsGlobeNewswireyesterday
- Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?24/7 Wall St.yesterday
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacksyesterday
- Are Wall Street Analysts Predicting Pfizer’s Stock Will Climb or Sink?Barchartyesterday
- What Sent Eli Lilly Stock Higher?Trefisyesterday
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.